FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2517308105> ?p ?o ?g. }

• W2517308105 endingPage "80553" @default.
• W2517308105 startingPage "80543" @default.
• W2517308105 abstract "// Elena Andreucci 1, 2, * , Paola Francica 1, 2, 4, * , Antony Fearns 2, 5 , Lesley-Ann Martin 2 , Paola Chiarugi 1, 3 , Clare M. Isacke 2 , Andrea Morandi 1 1 Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy 2 The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom 3 Tuscany Tumor Institute (ITT) and Excellence Centre for Research, Transfer and High Education DenoTHE, Florence, Italy 4 Current address: Department of Clinical Research, Radiation Oncology Laboratory, University of Bern, Bern, Switzerland 5 Current address: The Francis Crick Institute, Mill Hill Laboratory, The Ridgeway, London, United Kingdom * Equal first author contribution Correspondence to: Clare M. Isacke, email: clare.isacke@icr.ac.uk Andrea Morandi, email: andrea.morandi@unifi.it Keywords: RET, GDNF, endocrine therapy, aromatase inhibitors, resistance Received: March 15, 2016      Accepted: August 24, 2016      Published: September 02, 2016 ABSTRACT The majority of breast cancers are estrogen receptor positive (ER+). Blockade of estrogen biosynthesis by aromatase inhibitors (AIs) is the first-line endocrine therapy for post-menopausal women with ER+ breast cancers. However, AI resistance remains a major challenge. We have demonstrated previously that increased GDNF/RET signaling in ER+ breast cancers promotes AI resistance. Here we investigated the efficacy of different small molecule RET kinase inhibitors, sunitinib, cabozantinib, NVP-BBT594 and NVP-AST487, and the potential of combining a RET inhibitor with the AI letrozole in ER+ breast cancers. The most effective inhibitor identified, NVP-AST487, suppressed GDNF-stimulated RET downstream signaling and 3D tumor spheroid growth. Ovariectomized mice were inoculated with ER+ aromatase-overexpressing MCF7-AROM1 cells and treated with letrozole, NVP-AST487 or the two drugs in combination. Surprisingly, the three treatment regimens showed similar efficacy in impairing MCF7-AROM1 tumor growth in vivo . However in vitro , NVP-AST487 was superior to letrozole in inhibiting the GDNF-induced motility and tumor spheroid growth of MCF7-AROM1 cells and required in combination with letrozole to inhibit GDNF-induced motility in BT474-AROM3 aromatase expressing cells. These data indicate that inhibiting RET is as effective as the current therapeutic regimen of AI therapy but that a combination treatment may delay cancer cell dissemination and metastasis." @default.
• W2517308105 created "2016-09-16" @default.
• W2517308105 creator A5018736882 @default.
• W2517308105 creator A5022895279 @default.
• W2517308105 creator A5048102453 @default.
• W2517308105 creator A5061098872 @default.
• W2517308105 creator A5061435426 @default.
• W2517308105 creator A5082224541 @default.
• W2517308105 creator A5091210130 @default.
• W2517308105 date "2016-09-02" @default.
• W2517308105 modified "2023-10-12" @default.
• W2517308105 title "Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts" @default.
• W2517308105 cites W1529243395 @default.
• W2517308105 cites W1607879668 @default.
• W2517308105 cites W1861748936 @default.
• W2517308105 cites W1882882294 @default.
• W2517308105 cites W1990883066 @default.
• W2517308105 cites W1991766942 @default.
• W2517308105 cites W1992533338 @default.
• W2517308105 cites W2000744297 @default.
• W2517308105 cites W2013956549 @default.
• W2517308105 cites W2016809800 @default.
• W2517308105 cites W2031013232 @default.
• W2517308105 cites W2071221756 @default.
• W2517308105 cites W2083647855 @default.
• W2517308105 cites W2096993465 @default.
• W2517308105 cites W2110922728 @default.
• W2517308105 cites W2110928253 @default.
• W2517308105 cites W2112145459 @default.
• W2517308105 cites W2138033496 @default.
• W2517308105 cites W2143439281 @default.
• W2517308105 cites W2150353536 @default.
• W2517308105 cites W2157488188 @default.
• W2517308105 cites W2167188058 @default.
• W2517308105 cites W2169988894 @default.
• W2517308105 cites W2170908060 @default.
• W2517308105 doi "https://doi.org/10.18632/oncotarget.11826" @default.
• W2517308105 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5348339" @default.
• W2517308105 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27602955" @default.
• W2517308105 hasPublicationYear "2016" @default.
• W2517308105 type Work @default.
• W2517308105 sameAs 2517308105 @default.
• W2517308105 citedByCount "27" @default.
• W2517308105 countsByYear W25173081052017 @default.
• W2517308105 countsByYear W25173081052018 @default.
• W2517308105 countsByYear W25173081052019 @default.
• W2517308105 countsByYear W25173081052020 @default.
• W2517308105 countsByYear W25173081052021 @default.
• W2517308105 countsByYear W25173081052022 @default.
• W2517308105 countsByYear W25173081052023 @default.
• W2517308105 crossrefType "journal-article" @default.
• W2517308105 hasAuthorship W2517308105A5018736882 @default.
• W2517308105 hasAuthorship W2517308105A5022895279 @default.
• W2517308105 hasAuthorship W2517308105A5048102453 @default.
• W2517308105 hasAuthorship W2517308105A5061098872 @default.
• W2517308105 hasAuthorship W2517308105A5061435426 @default.
• W2517308105 hasAuthorship W2517308105A5082224541 @default.
• W2517308105 hasAuthorship W2517308105A5091210130 @default.
• W2517308105 hasBestOaLocation W25173081051 @default.
• W2517308105 hasConcept C121608353 @default.
• W2517308105 hasConcept C126322002 @default.
• W2517308105 hasConcept C143998085 @default.
• W2517308105 hasConcept C2776166826 @default.
• W2517308105 hasConcept C2776215463 @default.
• W2517308105 hasConcept C2778504769 @default.
• W2517308105 hasConcept C2778812593 @default.
• W2517308105 hasConcept C2779490328 @default.
• W2517308105 hasConcept C502942594 @default.
• W2517308105 hasConcept C530470458 @default.
• W2517308105 hasConcept C71924100 @default.
• W2517308105 hasConcept C84606932 @default.
• W2517308105 hasConceptScore W2517308105C121608353 @default.
• W2517308105 hasConceptScore W2517308105C126322002 @default.
• W2517308105 hasConceptScore W2517308105C143998085 @default.
• W2517308105 hasConceptScore W2517308105C2776166826 @default.
• W2517308105 hasConceptScore W2517308105C2776215463 @default.
• W2517308105 hasConceptScore W2517308105C2778504769 @default.
• W2517308105 hasConceptScore W2517308105C2778812593 @default.
• W2517308105 hasConceptScore W2517308105C2779490328 @default.
• W2517308105 hasConceptScore W2517308105C502942594 @default.
• W2517308105 hasConceptScore W2517308105C530470458 @default.
• W2517308105 hasConceptScore W2517308105C71924100 @default.
• W2517308105 hasConceptScore W2517308105C84606932 @default.
• W2517308105 hasIssue "49" @default.
• W2517308105 hasLocation W25173081051 @default.
• W2517308105 hasLocation W25173081052 @default.
• W2517308105 hasLocation W25173081053 @default.
• W2517308105 hasLocation W25173081054 @default.
• W2517308105 hasLocation W25173081055 @default.
• W2517308105 hasLocation W25173081056 @default.
• W2517308105 hasOpenAccess W2517308105 @default.
• W2517308105 hasPrimaryLocation W25173081051 @default.
• W2517308105 hasRelatedWork W1491737910 @default.
• W2517308105 hasRelatedWork W1966100371 @default.
• W2517308105 hasRelatedWork W2007182497 @default.
• W2517308105 hasRelatedWork W2015807835 @default.
• W2517308105 hasRelatedWork W2028465294 @default.
• W2517308105 hasRelatedWork W2033747658 @default.

• next